Outcomes in patients that have undergone coronary artery bypass grafting operation. Surgery
Conditions
Interventions
Randomization Process:
1. Participant List Creation:
- Developed a comprehensive list encompassing all eligible cardiovascular disease patients who had undergone coronary artery bypass grafting, ea
Sponsors
China Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with cardiovascular diseases and underwent coronary artery bypass grafting operation surgery for the first time; 2. Patients or their direct caregivers were capable of using web-based social media (such as WeChat and QQ); 3. Age > 18 years old; 4. In good mental conditions and proper communication abilities; 5. Willing the taking part in this study voluntarily and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Had cognitive or psychiatric disorders; 2. Combined with other severe organ dysfunctional disorders; 3. Unwilling to cooperate with researchers for any reason and refusal of continuing caring; 4. Lack of vision, speaking, reading and writing abilities; 5. The emergency of acute psychological or physical incidents; 6. Death after CABG operation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using self report: 1. Anxiety is measured using the Hospital Anxiety and Depression Scale (HADS)-A on the first day after discharge (M0), at 3rd-month (M3), 6th-month (M6), 9th-month (M9) and 12th-month (M12) after discharge. 2. Depression is measured using the Hospital Anxiety and Depression Scale (HADS)-D on the first day after discharge (M0), at 3rd-month (M3), 6th-month (M6), 9th-month (M9) and 12th-month (M12) after discharge. 3. Quality of life (QoL) is measured using the 12-Item Short-Form Health Survey (SF-12) on the first day after discharge (M0), at 3rd-month (M3), 6th-month (M6), 9th-month (M9) and 12th-month (M12) after discharge. 4. The occurrence of major adverse cardiac and cerebrovascular events (MACCE) is monitored and recorded within the whole 36-month follow-up period among all participants in this study. | — |
Secondary
| Measure | Time frame |
|---|---|
| The medication compliance is measured using a Chinese version of Morishy’s Medication Adherence Scale (MMAS-8) on the first day after discharge (M0), at 3rd-month (M3), 6th-month (M6), 9th-month (M9) and 12th-month (M12) after discharge. | — |
Countries
China
Contacts
Public ContactYan Jiang
Outcome results
None listed